Risk factors

The risk profile is dominated by severe liquidity concerns, ongoing operating losses, and a looming going concern doubt. The company faces high dependence on third-party manufacturers, unproven artificial intelligence drug discovery technologies, and early-stage preclinical assets. Operations are threatened by the need for additional capital raising, which risks significant dilution for existing stockholders.

Heavy reliance on Amazon and third-party platforms accounts for 99 percent of sales and creates major concentration risk.

Company faces historical net losses of $3,786,597 in 2024 and relies heavily on its top three content suppliers for 44% of content costs.

Operating losses of $1,946,734 and net losses of $2,281,742 for the year ended June 30, 2024 dominate the risk profile. Auditors issued a going concern opinion regarding ability to continue. Customer concentration risk is high with Pro-Link, Inc. accounting for 14% of revenue.

Accuray relies heavily on sales of the CyberKnife and TomoTherapy platforms, which face market acceptance hurdles. The company carries significant debt, including $100.0 million in convertible notes and credit facilities. International operations and single-source component suppliers expose the business to supply chain disruptions.

Campbell's risk profile is dominated by commodity price inflation, supply chain dependencies, and heavy indebtedness.

Lite Strategy is actively exploring strategic alternatives and has discontinued clinical programs like voruciclib and ME-344, implementing a workforce reduction. Significant risks include potential delisting from Nasdaq, activist pressure from major shareholders Anson Advisors and Cable Car Capital, and the need to secure additional capital if development resumes.

Nutanix faces intense competition from legacy IT vendors and public cloud providers in the enterprise IT market. The company must manage historical GAAP net losses, totaling $124.8 million in fiscal 2024. Growth depends heavily on indirect channel partners, international markets, and successful subscription-based cloud transitions.

Rezolute faces primary risks around clinical trial execution, regulatory approvals, third-party manufacturing dependencies, and patent protection for its drug candidates.

This is an initial filing with no prior year risk factors. Risk is dominated by going concern doubts, reliance on unlaunched products, single-source suppliers, and strict regulatory and intellectual property dependencies.

Marygold is a holding company dependent on USCF Investments for 58% of revenues. It operates diversified food and financial technology businesses with key-person concentration.

Pluri relies heavily on external capital raising and equity sales to fund its cash-constrained operations. The company faces significant regulatory, development, and commercialization hurdles across cell therapy, food tech, and agriculture. Nasdaq listing compliance is threatened due to a failure to meet stockholders equity requirements.